Helix BioPharma reports Q2 2008 highlights, financi...(ilings in the U.S. and Europe respective...)

Research and development expenditures related to the Phase II trial in Sweden are below the Company's original projections. This is attributable to a lower patient enrollment rate. Helix is currently in discussion with the regulatory authorities in Sweden as it relates to a protocol amendment put forth by the Company to restore the recruitment rate to the original projections that forecasted patient enrollment to be completed by the end of the 2008 calendar year. In order to achieve the enrollment completion timeline previously projected, the Company will have to expand the trial to other jurisdictions and multiple sites and, therefore, incur additional costs.

With the recent private placement, the Company is now in a better position to expedite the commercialization of its new drug candidates and expects research and development expenditures to increase in the latter half of fiscal 2008 and into fiscal 2009.

Operating, general & administration

Operating, general & administration expenses totaled $1,245,000 and $2,558,000, respectively, for the three and six month periods ended January 31, 2008, compared to $1,578,000 and $2,447,000, respectively for the same periods a year ago. Lower operating, general and administration expenses for the three month period ended January 31, 2008, were mainly the result of lower costs associated with the Company's annual shareholder meeting held on January 29, 2008. These costs were offset by additional costs incurred for wages, audit and consultancy services in the quarter.

For the six month period ended January 31, 2008, operating, general and administration expenses were marginally higher, with higher wages, audit and consultancy services along with a one-time charge in the first quarter of fiscal 2008 related to the resignation of the Company's then Chairman being partially offset by lower costs for the Company's annual shareholder meeting.
'/>"/>